Immune checkpoint inhibitors have shown promising results in different cancers, and correlation between immune infiltration, expression of programmed death-ligand 1 (PD-L1) by tumor cells and response to immunotherapy has been reported. There is limited knowledge regarding the immune microenvironment of small bowel (SB) neuroendocrine tumors (NETs). This work was aimed at characterizing the immune landscape of SB NETs. Expression of PD-L1 and programmed death-1 (PD-1) was evaluated by immunohistochemistry in 102 surgically resected, primary NETs of the duodenum, jejunum and ileum. Extent and characteristics of the tumor-associated immune infiltrate were also assessed and investigated in their prognostic potential. We detected the expression of PD-L1 in ≥1 and ≥50% of tumor cells in 40/102 (39%; 95% CI, 30-49%) and 14/102 (14%; 95% CI, 8-22%) cases respectively. Intratumor host immune response was apparently absent in 35/102 cases (34%; 95% CI, 25-44%), mild to moderate in 46/102 samples (45%, 95% CI, 35-55%), intense in 21/102 tumors (21%, 95% CI, 13-30%). Expression of PD-L1 and extent of immune infiltration were significantly higher in duodenal NETs as compared with jejunal/ileal NETs. A marked peritumoral host response was organized as ectopic lymph node-like structures in 18/102 cases (18%; 95% CI, 11-26%). Neither PD-L1 expression nor the degree of immune infiltration showed any prognostic significance. Overall, the immune landscape of SB NETs is heterogeneous, with adaptive immune resistance mechanisms prevailing in duodenal NETs. Clinical trials of immune checkpoint inhibitors should take into account the immune heterogeneity of SB NETs.
Introduction
Neuroendocrine tumors (NETs) of the small bowel (SB) represent the most common type of gastrointestinal NET (Frilling et al. 2012) . The incidence of SB NETs has increased substantially in recent years, and prolonged survival durations have been reported over time as therapeutic options improved (Dasari et al. 2017) . Nevertheless, the long-term outcome of patients with stage IV disease remains poor and new treatments including immune checkpoint inhibitors are currently being investigated (Pavel & Sers 2016) .
During tumorigenesis, cancer cells exploit a number of immune checkpoint pathways including the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis to avoid detection by the adaptive immune system. Checkpoint blockade has demonstrated dramatic antitumor activity in various solid cancers, and tumor PD-L1 expression as well as tumor lymphocyte infiltration have been described as predictors of response (Teng et al. 2015) .
Very little is known regarding the immune microenvironment of SB NETs, as well as their expression of immune checkpoint molecules. Circulating antigenspecific CD8 + T cells have been detected in patients with midgut carcinoids (Vikman et al. 2008) . However, a decreased proliferative capability has been shown for T cells from NET patients as compared with those from normal controls, probably as result of suppressed levels of systemic Th1-promoting cytokines and increased numbers of immunosuppressive T reg lymphocytes (Vikman et al. 2009) . Recently, tumor expression of PD-L1 has been reported in 22% of 32 patients with primarily high-grade, foregut-or hindgut-derived neuroendocrine neoplasms (Kim et al. 2016) . In a very heterogeneous cohort of 57 patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms, the expression of PD-L1 was observed in 0, 78 and 100% of G1, G2 and G3 tumors respectively (Cavalcanti et al. 2017) . In a series of 37 patients with poorly differentiated digestive neuroendocrine carcinomas (NECs), PD-L1 positivity was demonstrated in 14% of tumors (Roberts et al. 2017) . In another study of 62 patients with SB G1/G2 NETs, expression of PD-L1 within tumor cells was detected in 13% of samples, while infiltration of PD-1-positive lymphocytes was observed in 23% of cases (Lamarca et al. 2018) In order to characterize the immune landscape of primary SB NETs, we investigated the expression of PD-L1 and PD-1 on 102 surgically resected tumors of the duodenum, jejunum and ileum. We also assessed the extent and characteristics of the tumor-associated immune infiltrate, providing the first description of the immune microenvironment of SB NETs.
Patients and methods

Patient selection
Approval for data collection and analysis was obtained from the Institutional Review Board (IRB) of the University of South Florida (Tampa, FL, USA). Patient consent was not required by IRB given the retrospective nature of the study and the fact that the study posed no risk to patients. We retrospectively examined 102 patients with SB NETs whose primary tumors were resected at Moffitt Cancer Center between 2000 and 2015. The following information was collected by review of patient medical records: demographics, date of initial diagnosis, location of primary tumor, initial tumor stage according to the American Joint Committee on Cancer (AJCC) 2010 classification (Rindi et al. 2007) , as well as follow-up and survival data. Pathological information including tumor grade by World Health Organization (WHO) criteria (Rindi & Arnold 2010) , tumor size and presence of perineural or lymphovascular invasion were obtained by review of surgical pathology reports.
Evaluation of tumor lymphocytic infiltration
Selected hematoxylin and eosin (H&E)-stained slides were inspected by two experienced neuroendocrine pathologists (D C and S A D) to confirm the original diagnosis. Formalin-fixed paraffin-embedded (FFPE) blocks representative of the tumor/non-tumor interface were chosen for both assessment of immune infiltration and immunohistochemistry (IHC) analysis. Lymphocytes were counted in five representative areas and their average number was scored into four categories: no infiltration (0 cells/5 HPF), mild infiltration (1-10/5 HPF), moderate infiltration (11-50/5 HPF) and intense infiltration (>50/5 HPF). Sections were examined independently by D C and S A D; in case of disagreement, a consensus was reached after joint review at a multihead microscope. The readers were blinded to the patient clinical outcome.
Immunohistochemistry
Immunohistochemistry (IHC) was used to evaluate the expression of PD-L1 and PD-1 on all available cases (n = 102). Intra-and peri-tumoral immune infiltration was characterized by using mAbs against CD3, CD4, CD8, CD20, CD21, CD27, CD79a, CD138, FOXP3 and Ki-67 in a subset of samples (n = 20) randomly selected within the original cohort. FFPE tissue sections of 4 µm in thickness were stained using the avidin-biotin complex method, as previously described (Coppola et al. 2011) . Normal human tonsil tissue was used as a positive control for all staining. Parallel tests without the primary antibody served as negative control. Supplementary Table 1 (see section on supplementary data given at the end of this article) details dilutions, incubation times, clone and source for each mAb. For PD-L1 expression, both the intensity of the staining and the percentage of positive tumor cells were estimated. Staining intensity was scored considering 0 as negative or trace, 1 as weak, 2 as moderate and 3 as high. Various cut-offs were used for determining PD-L1 positivity, as summarized in Supplementary  Table 2 . Immunoreactivity for T cell markers including PD-1, CD3, CD4, CD8, CD27 and FOXP3 was detected in the tumor-infiltrating lymphocytes, while CD21 was used as marker of dendritic cells. B lymphocytes and B lymphocyte precursors were localized by CD20 and CD79a respectively, while CD138 + cells were interpreted as plasma cells. Immune cell proliferation was assessed by Ki-67 labeling. Immunoreactive cells were counted using the same criteria described above for the determination of lymphocytic infiltration on H&E-stained sections.
Statistical analysis
Descriptive statistics were used for patient demographics. The distribution of covariates was compared across groups using χ 2 , Fisher's test or ANOVA for categorical variables and Mann-Whitney test for continuous data. Pearson's test was used to assess the correlation between immune infiltration and the count of CD3 + cell. Overall survival (OS) was measured from date of initial diagnosis until death from any cause or last known follow-up. Cancerspecific survival (CSS) was calculated from the date of diagnosis until cancer-related death. Survival curves were estimated using the Kaplan-Meier method and compared by the log-rank test. Exact 95% CIs were calculated for each proportion of interest. All tests were two-sided and statistical significance was declared when P ≤ 0.05. Statistical analysis was conducted using MedCalc statistical software 12.7 (MedCalc Software bvba, Ostend, Belgium).
Results
Demographics and tumor characteristics
Demographic variables and clinicopathological characteristics are listed in Table 1 . The median age at diagnosis was 60 years. Presence of the carcinoid syndrome was documented in 23% of patients at baseline. The majority of patients (87%) had ileal primaries, and the median tumor size was 1.9 cm. Sixty-nine percent had lymph node metastases, and stage IV disease was diagnosed in 54% of cases. Liver (47%) and peritoneum (10%) were the main sites of distant metastases. The majority of tumors (92%) were low grade. Most patients were either treatment naïve (48/102) or had received only somatostatin analogs (41/102) for a median of 2 months (range 1-13 months) before resection of the primary tumor.
PD-1 and PD-L1 expression in SB NETs
All samples were assessable for PD-1 and PD-L1 expression.
No immunoreactivity for PD-1 was observed in tumor cells across all examined cases. When PD-L1 positivity was defined by membranous staining in either ≥1 or ≥5% of tumor cells, we interpreted 40 of 102 cases as positive (39%; 95% CI, 30-49%). In PD-L1-positive tumors, Endocrine-Related Cancer the staining intensity was weak, moderate and high in 21 (52%; 95% CI, 37-67%), 15 (38%; 95% CI, 24-53%) and 4 (10%; 95% CI, 4-23%) samples respectively. When PD-L1 positivity was defined by membranous staining in ≥50% of tumor cells, a positive staining was detected in 14/102 (14%; 95% CI, 8-22%) samples. Staining intensity was weak, moderate and high in eight (57%; 95% CI, 33-79%), three (21%; 95% CI, 8-48%) and three cases respectively (Fig. 1A) . Overall, interobserver agreement rate for PD-L1 expression was 85%. To mitigate potential biases deriving from the time-dependent fading of PD-L1 expression in FFPE samples, cases older than 3 years (n = 72; 71%) were analyzed separately. In this group, PD-L1 positivity was observed in 28/72 (39%; 95% CI, 28-50%) and 8/72 (11%; 95% CI, 6-20%) samples when the cut-off was set at ≥1 or ≥50% of tumor cells respectively.
As depicted in Fig. 1B and C, duodenal NETs showed significantly higher PD-L1 positivity compared with jejunal/ileal NETs. Of the 14 samples showing PD-L1 expression in ≥50% of tumor cells, seven were duodenal. There were no differences in PD-L1 expression by other clinicopathological characteristics (Table 2) . Rates of PD-L1 expression resulted similar when local tumors (N0M0) were compared to N+ tumors and M+ tumors.
Immune infiltration in SB NETs
Intratumor infiltration of immune cells was observed in 67/102 samples (66%; 95% CI, 56-74%), while no apparent host immune response was noted in the remaining 35 cases (34%; 95% CI, 26-44%). The density of immune infiltration was mild to moderate in 46/67 cases (69%; 95% CI, 57-78%) and intense in 21/67 samples (31%, 95% CI, 21-43%) (Fig. 2) . In 18/102 tumors (18%; 95% CI, 11-26%), there was a marked peritumoral host response that was organized as ectopic lymph nodes (ELNs) (Fig. 2D ). This response was particularly evident at the invasive edge of the tumors and was observed in 4, 5 and 9 samples with absent, moderate and intense intratumor immune infiltration respectively (P = 0.005). The presence of ELNs appeared to be associated with PD-L1 expression in ≥50% of tumor cells (P = 0.0003), but there was no statistically significant correlation with PD-L1 staining in ≥1% of tumor cells (P = 0.06). ELNs were detected more frequently in duodenal tumors as compared with jejunoileal NETs (P = 0.0009). As summarized in Table 3 , the density of the immune infiltration was significantly higher in duodenal tumors as compared with jejunoileal NETs (P = 0.0007). Moreover, there was a significant association between tumor PD-L1 expression and the extent of host immune response. No differences were seen between local tumors, N+ tumors and M+ tumors in terms density of immune infiltration. Figure 3 summarizes the main features of the immune microenvironment of SB NETs.
IHC characterization of the intratumor immune response
Intratumor infiltration of PD-1-positive lymphocytes was observed in 9/102 samples (9%; 95% CI, 5-16%). Of these, seven were of ileal origin and two of duodenal origin. The density of the infiltration was considered mild and intense in 3 and 6 tumors respectively. There was no correlation between PD-L1 expression and intratumor infiltration by PD-1-positive lymphocytes (P = 0.07), while PD-1-positive infiltration significantly correlated with PD-L1 staining intensity (P < 0.0001). No association was found between infiltration by PD-1-positive cells and tumor grade (P = 0.54).
To further investigate the cellular makeup of the host immune response, we carried out serial IHC studies in 20 tumors randomly selected from our cohort (n = 9 cases with mild/moderate immune infiltration; n = 11 cases with intense immune infiltration on H/E). Infiltrating CD3 + and CD20 + lymphocytes were found in 17/20 (85%; 95% CI, 64-95%) and 10/20 (50%; 95% CI, 30-70%) samples. There was a significant correlation between the density of the immune infiltration by H/E and CD3 + cell count (r=0.77; 95% CI, 0.39-0.93; P = 0.0013). The degree of CD3 + infiltration positively correlated with the expression of PD-L1 by tumor cells (P = 0.03). Infiltrating CD4 + and CD8 + lymphocytes were detected in 15/20 (75%; 95% CI, 53-89%) and 16/20 (80%; 95% CI, 58-92%) tumors respectively. Tumor-infiltrating CD27 + memory T cells were observed in 17/20 (85%; 95% CI, 64-95%) cases, while FOXP3 + T regulatory cells were found in 5/20 (25%; 95% CI, 11-47%) samples. Scattered CD138 + plasma cells were detected within the tumor parenchyma in only 2/20 (10%; 95% CI, 3-30%) samples. No CD21 + dendritic cells could be found within tumors.
IHC characterization of ELNs
We assessed the composition of ELNs in all ELN-positive samples (n = 18) by IHC. As depicted in Fig. 4 , the majority of CD3 + T cells were located in the parafollicular 
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Endocrine-Related Cancer suggested by the expression of Ki-67 within the pseudogerminal centers in all cases analyzed, thus supporting the hypothesis that the described lymphoid aggregates represent secondary and/or tertiary lymphoid structures.
Prognostic value of PD-L1 expression in stage IV SB NETs
Among 55 patients with metastatic SB NET, 16 had died and 39 were alive at the time of data cut-off. Seven deaths were known to be directly related to progressive metastatic disease, seven were possibly related to disease progression and two were not tumor related. Only one patient with duodenal NET had metastatic disease and was alive at the time of data cut-off. After a median follow-up of 60 months (range, 23-182 months), the 5-year and 10-year OS rates were 75% (±6%) and 59% (±10%) respectively. The 5-year and 10-year CSS rates were 77% (±6%) and 70% (±8%). There was no correlation between OS or CSS and tumor expression of PD-L1, irrespective of the cut-off used for defining staining positivity (Supplementary Fig. 1 ).
Prognostic value of immune infiltration in stage IV SB NETs
Among patients with metastatic SB NET, intratumor immune infiltration was absent in 17/55 cases, mild to moderate in 28 cases and intense in 10 cases. There was no significant difference in terms of both OS and CSS according to the degree of immune infiltration. Neither ELN presence nor intratumor infiltration by PD-1-positive cells had an impact on OS or CSS ( Supplementary Fig. 2 ). 
Discussion
Data on expression of immune checkpoint molecules in SB NETs are limited. Prior studies (Kim et al. 2016 , Cavalcanti et al. 2017 , Roberts et al. 2017 , Lamarca et al. 2018 have been limited by small sample size, inclusion of heterogeneous cohorts of tumors and lack of IHC standardization. Yet, accurate information on intratumor immune infiltration and expression of PD-L1 by tumor cells is critically important to define the immune environment status of SB NETs and potentially identify subgroups of patients suitable for emerging immunotherapy approaches. This study represents, to our knowledge, the largest series to examine PD-L1 expression and tumor-associated immune infiltration in a homogeneous population of patients with G1/G2, SB NETs. We included in our analysis only patients who underwent surgical resection of duodenal, jejunal or ileal primaries in order to avoid possible overestimation or underestimation of PD-L1 expression resulting from inadequate/unrepresentative biopsy sampling and evaluation of metastatic sites. To minimize the biases possibly deriving from the intratumoral heterogeneity of PD-L1 expression, all samples were analyzed at the tumor/non-tumor interface.
Results of our analysis show that PD-L1 is expressed in 39 and 14% of samples when the cut-off for IHC positivity determination is set at ≥1/5% or ≥50% of tumor cells, respectively. Interestingly, expression of PD-L1 appears to be significantly higher in duodenal NETs, where staining positivity in ≥50% of tumor cells was observed in 70% of tumors. The rate of PD-L1 expression observed in our cohort appears higher than rates preliminarily reported by other groups. A complete absence of membranous PD-L1 expression was described in a series of 64 SB NETs (da Silva et al. 2018) , while a positive staining in ≥5% of tumor cells was noted in 13% of samples analyzed in a study of 62 patients with small intestinal NETs (Lamarca et al. 2018) . Although different anti-PD-L1 Abs have been used in various reports, high levels of staining concordance have been recently shown when comparing such Abs (Gaule et al. 2016) . This suggests that the reported discordance of PD-L1 expression relies primarily on the high levels of intratumor heterogeneity already described for other cancers (Gaule et al. 2016) , rather than on Ab-based variability. In this context, the systematic analysis of PD-L1 expression at the tumor/non-tumor interface may have influenced our results, since increased levels of PD-L1 expression have been described at the invasive tumor edge (McLaughlin et al. 2016) .
Based on our data, about one-third of SB NETs appear immunologically ignorant (PD-L1 − ; TIL − ), and therefore, not suitable to immune checkpoint blockade. On the other hand, two-thirds of tumors were infiltrated by inflammatory cells, and intratumor immune infiltration was positively associated with PD-L1 expression. This suggests that 'immunologically hot' SB NETs upregulate PD-L1 in response to cytokines released by tumorinfiltrating lymphocytes as an adaptive immune resistance mechanism, rather than as consequence of constitutively activated oncogenic signaling pathways (Fig. 5) . In this context, it is intriguing to note that a type I microenvironment (PD-L1 + ; TIL + ), which is thought to be the immune subgroup most responsive to checkpoint blockade, predominates in duodenal vs jejunal/ileal NETs, making duodenal primaries preferred candidates for immunotherapy trials of SB NET patients.
In our series, only a minority of samples stained positively for PD-1, suggesting that infiltrating lymphocytes lack effective priming by tumor neoantigens. This is in line with the low mutational burden of SB NETs (Francis et al. 2013 ). An alternative hypothesis is that co-inhibitory receptors different from PD-1 (LAG-3, TIGIT, TIM-3, etc) are activated following lymphocyte activation.
About one-fifth of cases analyzed in our study had ELNs showing germinal center maturation at the invasive edge of the tumor, and their presence correlated with immune infiltration and PD-L1 expression. It is difficult to draw firm conclusions about the true nature of ELNs,
Figure 5
Immune microenvironment and PD-L1 regulation in SB NETs. After tumor initiation (A), SB NETs are infiltrated by inflammatory cells that produce pro-inflammatory cytokines, thus stimulating the expression of PD-L1 on tumor cells (B) . As result of the interaction between PD-L1 on the membrane of tumor cells and PD-1 on the surface of T lymphocytes, cross-primed CD8 + T cells become exhausted and lack their cytotoxic capability, leading to tumor immune escape (C). A full color version of this figure is available at https://doi.org/10.1530/ERC-18-0189.
but their prevalence in the duodenum, where secondary lymphoid structures such as Peyer's patches tend to be less common, suggests that they might be tertiary lymphoid structures (TLS). Described in a number of cancers, TLS have been involved in either immune-surveillance or immunesuppression (Coppola & Mulé 2008 , Colbeck et al. 2017 .
In line with prior observations in well-differentiated NETs (Kasajima et al. 2018 , Lamarca et al. 2018 , we found that both PD-L1 expression and immune infiltration had no impact on prognosis. Although the predictive ability of PD-L1 expression can be assessed only in prospective trials of immune checkpoint inhibitors, the heterogeneous immune landscape reported in our study for SB NETs suggests that highly variable patterns of response to immunotherapy may be encountered in the clinical setting for these malignancies.
This study has several limitations. First, our analysis was focused exclusively on primary tumors, thus hindering any possible considerations on the role of the immune microenvironment in the progression of NETs. Second, we systematically assessed the expression of PD-L1 only at the tumor/non-tumor interface. This strategy of staining standardization may have limited our ability to evaluate the intratumoral immune landscape.
Taken together, our data show that the immune landscape of SB NETs is heterogeneous, with adaptive immune resistance mechanisms prevailing in duodenal NETs rather than in jejunal/ileal carcinoids. Identification of patients more likely to respond to immunotherapy is key for the success of clinical trials of immune checkpoint inhibitors.
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